Trial Profile
Symbicort [budesonide/formoterol] in chronic obstructive pulmonary disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Mar 2008
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms SYMBIOSE
- Sponsors AstraZeneca
- 19 Mar 2008 QA'ed
- 14 Mar 2008 New trial record.